Background: The detection of high-risk human papillomavirus (HPV) DNA provides higher sensitivity but lower specificity than cytology for the identification of high-grade cervical intraepithelial neoplasia (CIN). This study compared the sensitivity and specificity of several adjunctive tests for the detection of high-grade CIN in a population referred to colposcopy because of abnormal cytology. Methods: 953 women participated in the study. Up to seven tests were carried out on a liquid PreservCyt sample: Hybrid Capture II (Digene), Amplicor (Roche), PreTect HPV-Proofer (NorChip), APTIMA HPV assay (Gen-Probe), Linear Array (Roche), Clinical-Arrays (Genomica), and CINtec p16
Introduction
High-risk human papillomavirus (HR-HPV) is a necessary factor for the development of cervical cancer (1) , but the presence of HR-HPV DNA does not invariably lead to disease. Recently, we showed that the detection of HR-HPV provides high sensitivity but has lower specificity than cytology for the identification of high-grade cervical lesions in a screening population in the United Kingdom (2) , and this finding has been replicated in several other studies (3) (4) (5) (6) (7) (8) (9) . In addition, prospective studies have shown that HPV DNA-positive women are significantly more likely to develop high-grade squamous intraepithelial lesions within 10 years than women with a negative HPV DNA test (10, 11) . If testing for HR-HPV DNA is to be used as a primary cervical screening test, refinements or additional tests are highly desirable to improve specificity while retaining its very high sensitivity.
The introduction of a liquid-based medium for collection of cytologic specimens has allowed other molecular techniques to be evaluated more easily as adjunctive or triage tests (12) . The aim of this study was to compare directly the sensitivity and specificity of several tests from the same sample for the detection of high-grade cervical intraepithelial neoplasia (CIN) in a population referred to colposcopy because of abnormal cytology. All the tests were compared against the gold standard of histopathology.
Materials and Methods
The study population comprised 953 women who had been referred to the colposcopy clinics at the Hammersmith and St. Mary's Hospitals in London between August 2005 and January 2007. Although not a screening population, the advantage was a broad range of outcomes and a high disease rate, which would enable accurate evaluation of sensitivity and specificity in a relatively small sample. Women were eligible if they had been referred as a result of one or more abnormal cervical smears, were not pregnant, had not been treated previously for CIN, nor had a hysterectomy. All women received a patient information sheet explaining the study and provided written consent. Approvals were obtained from the relevant local research ethics committees.
Before colposcopy, a cervical sample was obtained using a Cervex broom and placed in PreservCyt transport medium. Colposcopy was then done in the usual manner. The liquid-based cytology samples were transported to The Doctors' Laboratory, where an aliquot was first removed for cytology, processed using the ThinPrep system, and returned to the relevant cytopathology departments for reporting. The processing of the other tests was then done as follows:
NorChip PreTect HPV-Proofer tests were done by The Doctors' Laboratory using a second aliquot removed from the liquid-based cytology sample. The remainder of the sample was then sent to the laboratory at Cancer Research UK, where aliquots were removed for the other tests in the order: Digene Hybrid Capture II, Roche Amplicor, Gen-Probe APTIMA, Roche Linear Array, Genomica Clinical-Arrays, and mtm Laboratories CINtec p16
INK4a Cytology. To look for the potential of sample carryover, we did autocorrelations on results obtained from sequential samples assayed by NorChip PreTect HPV-Proofer, Hybrid Capture II, Amplicor, Linear Array, and a PCR test for HPV-16 and HPV-18, respectively, and found no evidence of a pattern. All tests were carried out in the Cancer Research UK laboratory according to standard manufacturers' instructions, except the APTIMA test, which was carried out by the manufacturer. The molecular testing laboratories were blinded to the cytology and histopathology results.
Reporting of CINtec p16 INK4a Cytology was carried out by Dr. Christine Bergeron according to a scoring method described recently (13, 14) .
Histopathology was first reported locally and then centrally reviewed by either Dr. Hilary Buckley (92% of samples) or Dr. Christine Bergeron (8% of samples), who were blinded to all study test results but did have access to the concurrent cytology. All results are presented based on the reviewed histopathology and the highest grade of abnormality seen in the biopsy or treatment specimen was used.
Laboratory Methods. In this study, the following assays were carried out and scored in strict accordance with the manufacturer's protocol.
(a) DNA-Based Detection Assays
Hybrid Capture II (Digene/Qiagen) detecting 13 HR-HPV genotypes collectively. The Hybrid Capture II assay requires 2 mL PreservCyt sample and is based on the hybridization of HPV DNA to a 13 Linear Array (Roche Diagnostics) detecting 37 highrisk and low-risk genotypes individually. HPV DNA was amplified from 1 mL PreservCyt using biotinylated PGMY primers and h-globin acted as sample control. Amplicons are hybridized to an array of genotype-specific and cross-reactive oligonucleotide probes before colorimetric detection. Linear Array aims to identify the DNA of 35 HPV genotypes with more appropriate primers (PYGM). Unfortunately, the manufacturer does not provide clear guidelines as to how the results should be scored. In this study, we only scored clear positive bands at least as strong as the low level h-globin band. DNA samples were amplified by 40 cycles of PCR.
Clinical-Arrays (Genomica) detecting 35 high-risk and low-risk genotypes individually. HPV DNA was amplified from 1 mL PreservCyt using biotinylated MY09/11 consensus primers hybridized to a low-density microarray of 37 HPV-type specific oligonucelotides for 45 cycles of amplification before colorimetric detection. A DNA sample control (CFTR) gene and an amplification reaction control are included.
(c) p16
INK4a Immunocytochemical Detection of Overexpression of the p16
INK4a Tumor Suppressor Gene (CINtec Cytology, mtm Laboratories) and Scoring Using Nuclear Morphology. Immunostaining was done using monoclonal antibody to p16
INK4a with anti-mouse as second antibody and detected by DAB chromogen. p16 INK4a score was based on nuclear assessment of brown stained cells by four criteria (13) . Cells positive for any one of these criteria were scored as 2. Cells positive for A and one other criterion were scored as 3, and cells positive for A and more than one other criterion were scored as 4. The sample score was the highest score observed.
In addition, two RNA-based detection assays were also carried out. These were PreTect HPV-Proofer (NorChip) assayed by The Doctors' Laboratory. PreTect HPV-Proofer is a realtime multiplex NASBA assay for isothermal amplification of E6/E7 mRNA expressed by 5 HR-HPV types (16, 18, 31, 33 , and 45) using proprietary primer sets. APTIMA (Gen-Probe) assayed by the manufacturer. The APTIMA assay is based on target capture, transcription-mediated amplification, and hybridization protection for the detection of E7 mRNA expression of 14 HR-HPV types.
Sample adequacy was assessed by a cellular DNA or RNA marker for all molecular assays, except Hybrid Capture II. Assay variability was controlled by including We calculated that a minimum of 500 patients would be needed to have 80% power to detect a change in sensitivity from 80% to 90% assuming a 25% prevalence of CIN2+ and a discordance rate of 3.6% (18 of 500). This number of subjects would give at least 90% power to detect improvements in specificity from 50% (common in triage) to 75%.
The gold standard was histologically confirmed highgrade CIN (CIN2+), but calculations were also made for histologically confirmed CIN3+. The sensitivity, specificity, and positive predictive value (PPV) of each test were computed and 95% exact binomial confidence intervals (95% CI) were obtained using exact binomial methods when necessary. Sensitivity and specificity were further studied by ROC analyses for concurrent cytology, Hybrid Capture II, Amplicor, and CINtec p16 INK4a Cytology score using different cutoff levels. Additional calculations of sensitivity, specificity, and PPV were carried out for different age groups. Agreement between the pairs of tests was assessed using Cohen's j statistic. Results for concurrent cytology are also given, but they are not comparable with the study tests because they were available to the pathologists when reading the histology specimens.
In the present analyses, only HR-HPV types were included for Linear Array and Clinical-Arrays (Genomica), and samples showing multiple unspecified types for Clinical-Arrays were removed from the statistical analyses.
Results and Discussion Figure 1 shows the study recruitment. Nine hundred ninety-nine women consented to participate in the study; however, 19 proved to be ineligible. In 27 cases, there was insufficient material for analysis. Thus, the tests from 953 women were analyzed. The median length of time between the referral smear and colposcopy was 2.4 months (interquartile range, 1.9-3.3; range, 0.6-50 months). The median age of the women was 29.9 years (interquartile range, 26.4-35.6). The age distribution is shown in Fig. 2 . Table 1 shows the results of the referral smears, where it can be seen that f23% of women had high-grade dyskaryosis and >75% had low-grade disease (borderline or mild dyskaryosis). Table 1 also shows the results of the cervical smear taken on the day of the colposcopy (concurrent smear). Although 27% of women had highgrade dyskaryosis, the percentage with low-grade dyskaryosis was only 46%, whereas in 26% of cases, this smear was normal. This may reflect the time interval between the two smears, during which some low-grade disease may have regressed, and also technique differences and the subjectivity of cytologic assessment. It should be noted that not all the referral smears were taken using liquid-based cytology, because the area was Figure 3 . Summary graph of the sensitivity and specificity results for the detection of CIN3+ (with 95% CI). in the process of a changeover during the study. All the colposcopy clinic (concurrent) smears were taken using liquid-based cytology. The results of the concurrent cytology were available to the pathologist when determining histologic outcome and so could not be independently evaluated. However, the results are shown in Table 2 for comparison. Over 45% of the women had either a normal colposcopy with no biopsy or a negative biopsy. Around 25% of women were found to have low-grade CIN, 8% had CIN2, and just below 20% had CIN3 or worse.
Sensitivity, specificity, and PPV for CIN2+ and CIN3+ of the different tests are reported in Table 2A to C, respectively, for all women, women aged <30 and z30 years. We have chosen to report separately results for CIN2+ and CIN3+ because CIN2 is less likely to progress and has greater variability in diagnosis. CIN3 has been shown to have greater reproducibility. Tables 2A to C and 3 also include the sensitivity for CIN2 alone.
Unfortunately, CINtec p16 INK4a Cytology testing was the last evaluation in the testing sequence, and there was not always sufficient sample to perform the test. The results pertaining to CINtec p16
INK4a Cytology are therefore from a subset of 534 (56%) women, including 10 women for which the results were not available. We therefore present the CINtec p16
INK4a Cytology results with the caveat that they should be interpreted with caution. In addition due to technical problems during the evaluation, the Genomica Clinical-Arrays results should also be interpreted with caution.
Sensitivity, specificity, and PPV for all the tests are shown in Table 2A . The sensitivity and specificity results for the tests are summarized in Figs. 3 and 4 , respectively, for CIN2+ and CIN3+. Four adjunctive tests had a sensitivity greater than 95% for high-grade disease (CIN2+ and CIN3+, respectively): Amplicor (98.9% and 99.5%), Hybrid Capture II (99.6% and 99.5%), Linear Array (98.2% and 99.0%), and APTIMA (95.2% and 97.4%). Of these, APTIMA showed the highest specificity (42.2% and 38.8%; Table 2A ). Linear Array had similar sensitivity to Hybrid Capture II and Amplicor, as has been shown previously, but in contrast to earlier studies (15) had a higher specificity at 32.8% for CIN2+ and 29.6% for CIN3+. Overall, the highest specificity (>70%) was achieved with the PreTect HPV-Proofer, but this test had relatively low sensitivity (Table 2A) . The CINtec p16 INK4a Cytology test (on a subset of samples) also gave lower sensitivity (83.0% and 92.7%), compared with HPV DNA tests, but had higher specificity (68.7% and 65.8%), approaching that of the PreTect HPV-Proofer (73.1% and 70.4%). The Genomica test (Clinical-Arrays) had performance characteristics that were dominated by those of the other tests. The Genomica results were less favorable than those obtained in other studies (16, 17) and may be due to the fact that 187 samples had ''multiple types'' results. The reasons for this are unclear despite a careful review of laboratory procedures on several occasions. When focusing on CIN3+, overall, sensitivity is slightly improved and specificity is slightly reduced; however, the ordering of the tests remains the same for both measures.
All tests showed a similar sensitivity in both younger (<30 years) and older women (z30 years), although CINtec p16
INK4a Cytology did better in the older age group and PreTect HPV-Proofer and Clinical-Arrays did slightly better in the younger age group for CIN3+. All tests, however, showed higher specificity in the older age group (Table 2B and C) .
When the population was restricted to women who had a single mild or only borderline dyskaryotic smears, the results were generally similar (Table 3) . For the four tests that showed the highest sensitivity (Hybrid Capture II, Amplicor, Linear Array, and APTIMA), specificity was f50% higher when only women with borderline dyskaryotic smears were considered (Supplementary Table S1 ). However, the relative performance of the tests was unchanged in these lower risk categories.
The results for CINtec p16 INK4a Cytology were less favorable than those in other recent publications (14) , which found a sensitivity of 100% in a low-grade squamous intraepithelial lesions population, with a specificity of 81.7%. However, there is a wide variation in the literature, which may be at least partly related to changes in and a lack of standardization in reporting of p16
INK4a cytology results (18) . It should also be remembered that the p16
INK4a samples in this study may have been suboptimal and further studies are required to fully evaluate this test. Table 4 shows the effects on sensitivity, specificity, and PPV of using different cutoffs for Hybrid Capture II, Amplicor, and CINtec p16
INK4a Cytology score in predicting histologically confirmed high-grade disease (CIN2+ and CIN3+). If the cutoffs for both Hybrid Capture II and Amplicor were raised (from 1 to z2 or z4 RLU/PC for Hybrid Capture II and from 0.2 to z1 or z2 RLU/PC for Amplicor), the sensitivity remained relatively unchanged, whereas the specificity slightly improved. Using a cutoff of z2 instead of z3 for the CINtec p16
INK4a Cytology score improved the sensitivity (83.0-97.2%) but had an unacceptable effect on specificity, which decreased from 68.7% to 35.9%. High concordance between Hybrid Capture II and Amplicor has been shown previously (15, (19) (20) (21) However, our results suggest that both tests might benefit from adjusting their positivity cutoff values (to z2 RLU/PC for Hybrid Capture II and z1 for Amplicor), which would improve their specificity and PPV, while having 
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